Patients with diabetes and chronic kidney disease (CKD) are at lower risk for cardiovascular (CV) events if they are treated with ‘Pioglitazone’.A research study concluded recently under the leadership of Christian Schneider of the University of Cologne, Germany established this result with evidences of clinical trials.
CKD, as defined by a ‘Glomerular Filtration Rate (GFR)’ lower […]

Click Here To Continue Reading